Advanced practice providers have the opportunity to instill hope in patients through education and personalized care.

An oral tablet formulation of zanubrutinib was approved for use in patients with certain lymphomas or leukemia and ...

UGN-102 has received FDA approval for use in patients with low-grade intermediate-risk non-muscle-invasive bladder cancer.